那屈肝素钙治疗急性冠状动脉综合征的疗效和安全性

Efficiency and safety of Fraxiparin for patients with acute coronary syndrome

目的:比较那屈肝素钙和依诺肝素钠治疗急性冠状动脉综合征的有效性和安全性。方法:137例急性冠状动脉综合征患者按随机原则平行分组后进行阳性对照试验。结果:治疗7d中,那屈肝素钙组未发生心脏死亡,依诺肝素钠组有2例发生心脏死亡,差别无统计学意义(P>0.05);d1～7两组均无心脏急性Q波心肌梗死。两组治疗前后肌酸激酶(CK)、肌酸激酶同功酶(CKMB)、肌钙蛋白T的改善均有统计学意义(P<0.05),但是两组治疗前后的改善情况差别无统计学意义(P>0.05)。治疗中偶见的不良反应为返酸和头晕,但停药后好转。结论:那屈肝素钙和依诺肝素钠同样为有效的治疗急性冠状动脉综合征的药物,可以明显改善症状和检验指标,治疗中两药均无严重的不良反应。

AIM： To evaluate the efficiency and safety of Fraxiparin for patients with acute coronary syndrome （ACS）. METHODS： 137 patients with ACS were randomly assigned to Fraxiparin treatment or enoxaparin treatment for seven days. RESULTS： 129 cases completed the whole trial and the results were obtained from ITT. The heart death rate is not statistically different between the two groups during the treatment. There are no Q segment acute myocardial infarction happened. Both drags statistically decreased CK, CKMB and TnT, There was no significant difference between the two groups regarding these changes. Only two minor adverse reactions happened and became normal soon after Nadroparin withdrew. CONCLUSION： Fraxiparin and enoxaparin have similar efficiency and safety in the treatment of patients with ACS.